LYZZ Capital — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Wugenwugen.comAug 2025 · $115M
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersAbingworthFidelity Investments+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.